öffnen / schließen
Wenn Sie diese Felder durch einen Klick aktivieren, werden Informationen an Facebook, Twitter oder Google in die USA übertragen und unter Umständen auch dort gespeichert. Näheres erfahren Sie hier: https://www.heise.de/ct/artikel/2-Klicks-fuer-mehr-Datenschutz-1333879.html

Medical Biotechnology in Germany 2005 - 2015 - 2025

The key economic data in medical biotechnology in Germany at a glance:

Sales of biopharmaceuticals increased in 2014 by 7% in real terms compared to 2013 and reached around 7.5 billion euros. Their share in the total pharmaceutical market (pharmacies and hospitals) increased from 21.4% to 22.0%.

The number of employees in medical biotechnology within German increased slightly to 37,715 (+3.7%). Most of them are highly qualified.

With a total of 47 newly approved medicinal products, 2014 was another strong year and —as in the previous year—nearly one third (30%, 14 drugs) were biopharmaceuticals.

The number of biopharmaceutical preparations in clinical development has increased from 587 to 604 (+3%) within the space of one year, and this reflects the continuing high investment in the biopharmaceutical pipeline.

In 2014, there were 389 companies involved in medical biotechnology in Germany (2013: 387).

Approved biopharmaceutical products155226
Biopharmaceutical products in the pipeline(1) 256604
mAbs(2) in the pipeline79357
Sales of biopharmaceuticals2,6 Mrd. €7,5 Mrd. €
Biopharmaceuticals market share12%22%
Share of biopharmaceuticals metabolism23%(3) 38%
Share of biopharmaceuticals oncology21%(3) 38%
Share of biopharmaceuticals immunology19%(3) 73%
Number of employees26.42037.715

(1) incl. biotechnological and genetically engineered vaccines

(2) monoclonal antibodies

(3) first breakdown in the Biotech-Report 2007 for the calendar year 2006

In order to leverage the enormous potential of medical biotechnology in Germany and to ensure continuous advances in medicine, the industry needs stable and innovation-friendly conditions. This is the only way to preserve the continuous cycle of appreciation and reimbursement of biopharmaceutical innovation, which in turn will lead to investment in research, development, and production—to the benefit of patients, society, and Germany.